TNFRSF17 and Miyoshi myopathy: CAR-T therapy is a cutting-edge modality in oncological immunotherapy29,30 and has been recognized as a potential therapeutic avenue for MM.31,32 BCMA is a target for MM CAR-T therapy due to its predominant expression on malignant cells.